Terazosin, a repurposed GPR119 agonist, ameliorates mitophagy and β-cell function in NAFPD by inhibiting MST1-Foxo3a signalling pathway

Abstract

GPR119 agonists are being developed to safeguard the function of pancreatic β-cells, especially in the context of non-alcoholic fatty pancreas disease (NAFPD) that is closely associated with β-cell dysfunction. This study aims to employ a drug repurposing strategy to screen GPR119 agonists and explore their potential molecular mechanisms for enhancing β-cell function in the context of NAFPD. MIN6 cells were stimulated with palmitic acid (PA), and a NAFPD model was established in GPR119^−/− mice fed with a high-fat diet (HFD). Terazosin, identified through screening, was utilized to assess its impact on enhancing β-cell function via the MST1-Foxo3a pathway and mitophagy. Terazosin selectively activated GPR119, leading to increased cAMP and ATP synthesis, consequently enhancing insulin secretion. Terazosin administration improved high blood glucose, obesity, and impaired pancreatic β-cell function in NAFPD mice. It inhibited the upregulation of MST1-Foxo3a expression in pancreatic tissue and enhanced damaged mitophagy clearance, restoring autophagic flux, and improving mitochondrial quantity and structure in β-cells. Nevertheless, GPR119 deficiency negated the positive impact of terazosin on pancreatic β-cell function in NAFPD mice and abolished its inhibitory effect on the MST1-Foxo3a pathway. Terazosin activates GPR119 on the surface of pancreatic β-cells, enhancing mitophagy and alleviating β-cell dysfunction in the context of NAFPD by suppressing the MST1-Foxo3a signalling pathway. Terazosin could be considered a priority treatment for patients with concomitant NAFPD and hypertension.

References

[1] Hales CM, Carroll MD, Fryar CD, Ogden CL. Prevalence of obesity and severe obesity among adults: United States, 2017-2018. NCHS Data Brief. 2020; 360: 1-8.

[2] Cooper AJ, Gupta SR, Moustafa AF, Chao AM. Sex/gender differences in obesity prevalence, comorbidities, and treatment. Curr Obes Rep. 2021; 10(4): 458-466.

[3] Oguoma VM, Coffee NT, Alsharrah S, et al. Prevalence of overweight and obesity, and associations with socio-demographic factors in Kuwait. BMC Public Health. 2021; 21(1): 667.

[4] Bashir MA, Yahaya AI, Muhammad M, Yusuf AH, Mukhtar IG. Prevalence of central obesity in Nigeria: a systematic review and meta-analysis. Public Health. 2022; 206: 87-93.

[5] Piché ME, Tchernof A, Després JP. Obesity phenotypes, diabetes, and cardiovascular diseases. Circ Res. 2020; 126(11): 1477-1500.

[6] Tariq H, Nayudu S, Akella S, Glandt M, Chilimuri S. Non-alcoholic fatty pancreatic disease: a review of literature. Gastroenterology Res. 2016; 9(6): 87-91.

[7] Shah N, Rocha JP, Bhutiani N, Endashaw O. Nonalcoholic fatty pancreas disease. Nutr Clin Pract. 2019; 34(Suppl 1): S49-S56.

[8] Weng S, Zhou J, Chen X, Sun Y, Mao Z, Chai K. Prevalence and factors associated with nonalcoholic fatty pancreas disease and its severity in China. Medicine. 2018; 97(26):e11293.

[9] Zhou J, Li ML, Zhang DD, et al. The correlation between pancreatic steatosis and metabolic syndrome in a Chinese population. Pancreatology. 2016; 16(4): 578-583.

[10] Singh RG, Yoon HD, Wu LM, Lu J, Plank LD, Petrov MS. Ectopic fat accumulation in the pancreas and its clinical relevance: a systematic review, meta-analysis, and meta-regression. Metabolism. 2017; 69: 1-13.

[11] Maetzel H, Rutkowski W, Panic N, et al. Non-alcoholic fatty pancreas disease and pancreatic exocrine insufficiency: pilot study and systematic review. Scand J Gastroenterol. 2023; 58: 1030-1037.

[12] Filippatos TD, Alexakis K, Mavrikaki V, Mikhailidis DP. Nonalcoholic fatty pancreas disease: role in metabolic syndrome, “prediabetes,” diabetes and atherosclerosis. Dig Dis Sci. 2022; 67: 26-41.

[13] Sahin S, Karadeniz A. Pancretic fat accummulation is associated with subclinical atherosclerosis. Angiology. 2022; 73: 508-513.

[14] Nieto Gutierrez A, McDonald PH. GPCRs: emerging anti-cancer drug targets. Cell Signal. 2018; 41: 65-74.

[15] Ritter K, Buning C, Halland N, Pöverlein C, Schwink L. G protein-coupled receptor 119 (GPR119) agonists for the treatment of diabetes: recent Progress and prevailing challenges. J Med Chem. 2016; 59(8): 3579-3592.

[16] Li NX, Brown S, Kowalski T, et al. GPR119 Agonism increases glucagon secretion during insulin-induced hypoglycemia. Diabetes. 2018; 67(7): 1401-1413.

[17] Ma L, Li J, Song H, et al. Lipotoxicity induced pancreatic beta cell damage is associated with GPR119/MST1/FoxO1 Pathway. Arch Med Sci. 2021. https://doi.org/10.5114/aoms/126556

[18] Zuo Z, Chen M, Shao X, et al. Design and biological evaluation of tetrahydropyridine derivatives as novel human GPR119 agonists. Bioorg Med Chem Lett. 2020; 30(4):126855.

[19] Nasteska D, Hodson DJ. GPR119 Agonism revisited: a novel target for increasing β-cell mass? Endocrinology. 2020; 161(2):bqz018.

[20] Manaithiya A, Alam O, Sharma V, Javed Naim M, Mittal S, Khan IA. GPR119 agonists: novel therapeutic agents for type 2 diabetes mellitus. Bioorg Chem. 2021; 113: 104998.

[21] Li H, Fang Y, Guo S, Yang Z. GPR119 agonists for the treatment of type 2 diabetes: an updated patent review (2014-present). Expert Opin Ther Pat. 2021; 31(9): 795-808.

[22] Allison M. NCATS launches drug repurposing program. Nat Biotechnol. 2012; 30(7): 571-572.

[23] Pushpakom S, Iorio F, Eyers PA, et al. Drug repurposing: progress, challenges and recommendations. Nat Rev Drug Discov. 2019; 18(1): 41-58.

[24] Hughes B. 2009 FDA drug approvals. Nat Rev Drug Discov. 2010; 9: 89-92.

[25] Jin G, Wong STC. Toward better drug repositioning: prioritizing and integrating existing methods into efficient pipelines. Drug Discov Today. 2014; 19: 637-644.

[26] Sonaye HV, Sheikh RY, Doifode CA. Drug repurposing: iron in the fire for older drugs. Biomed Pharmacother. 2021; 141: 111638.

[27] Jia G, Sowers JR. Hypertension in diabetes: an update of basic mechanisms and clinical disease. Hypertension. 2021; 78: 1197-1205.

[28] Kirk JK, Konen JC, Shihabi Z, Rocco MV, Summerson JH. Effects of terazosin on glycemic control, cholesterol, and microalbuminuria in patients with non—insulin-dependent diabetes mellitus and hypertension. Am J Ther. 1996; 3: 616-621.

[29] Shionoiri H, Gotoh E, Ito T, et al. Long-term therapy with terazosin may improve glucose and lipid metabolism in hypertensives: a multicenter prospective study. Am J Med Sci. 1994; 307(Suppl 1): S91-S95.

[30] Ma LR. The role of GPR119/MST1/FoxO1 pathway in lipid toxicity injury of pancreatic beta cells in mice. Ningxia Medical University 2018.

[31] Zheng M, Zhang X, Min X, Sun N, Kim KM. Cytoplasmic recruitment of Mdm2 as a common characteristic of G protein-coupled receptors that undergo desensitization. Biochem Biophys Res Commun. 2020; 530(1): 181-188.

[32] Qi H, Li Y, Liang H, et al. Screening and functional verification of miRNA regulating mouse mammalian ste20-like kinase 1. J Ningxia Med Univ. 2020; 42(7): 10.

[33] Li Y, Luan Y, Li J, et al. Exosomal miR-199a-5p promotes hepatic lipid accumulation by modulating MST1 expression and fatty acid metabolism. Hepatol Int. 2020; 14(6): 1057-1074.

[34] Li Y, Nie JJ, Yang Y, et al. Redox-unlockable nanoparticle-based MST1 delivery system to attenuate hepatic steatosis via the AMPK/SREBP-1c signaling Axis. ACS Appl Mater Interfaces. 2022; 14(30): 34328-34341.

[35] Wu Y, Zeng L, Zhao S. Ligands of adrenergic receptors: a structural point of view. Biomolecules. 2021; 11(7): 936.

[36] Ardestani A, Maedler K. MST1: a promising therapeutic target to restore functional beta cell mass in diabetes. Diabetologia. 2016; 59(9): 1843-1849.

[37] Wang J, Qi Z, Wu Y, et al. Discovery of IHMT-MST1-39 as a novel MST1 kinase inhibitor and AMPK activator for the treatment of diabetes mellitus. Signal Transduct Target Ther. 2023; 8(1): 143.

[38] Wu Y, Qi Z, Wang B, et al. Discovery of IHMT-MST1-58 as a novel, potent, and selective MST1 inhibitor for the treatment of type 1/2 diabetes. J Med Chem. 2022; 65(17): 11818-11839.

[39] Ardestani A, Li S, Annamalai K, et al. Neratinib protects pancreatic beta cells in diabetes. Nat Commun. 2019; 10(1): 5015.

[40] Zhang M, Zhang L, Hu J, et al. MST1 coordinately regulates autophagy and apoptosis in diabetic cardiomyopathy in mice. Diabetologia. 2016; 59(11): 2435-2447.

[41] Hu Y, Wang B, Wang L, Wang Z, Jian Z, Deng L. Mammalian STE20-like kinase 1 regulates pancreatic cancer cell survival and migration through Mfn2-mediated mitophagy. Mol Med Rep. 2020; 22(1): 398-404.

[42] Wilkinson DS, Hansen M. LC3 is a novel substrate for the mammalian Hippo kinases, STK3/STK4. Autophagy. 2015; 11(5): 856-857.

[43] Ardestani A, Maedler K. MST1 deletion protects β-cells in a mouse model of diabetes. Nutr Diabetes. 2022; 12(1): 7.

[44] Lee KK, Murakawa M, Nishida E, et al. Proteolytic activation of MST/Krs, STE20-related protein kinase, by caspase during apoptosis. Oncogene. 1998; 16(23): 3029-3037.

[45] Shim JY, Chung JO, Jung D, et al. Parkin-mediated mitophagy is negatively regulated by FOXO3A, which inhibits Plk3-mediated mitochondrial ROS generation in STZ diabetic stress-treated pancreatic β cells. PLoS One. 2023; 18(5):e0281496.

[46] Gupta P, Sharma G, Lahiri A, Barthwal MK. FOXO3a acetylation regulates PINK1, mitophagy, inflammasome activation in murine palmitate-conditioned and diabetic macrophages. J Leukoc Biol. 2022; 111(3): 611-627.

[47] Shang Y, Yan Y, Chen B, Zhang J, Zhang T. Over-expressed MST1 impaired spatial memory via disturbing neural oscillation patterns in mice. Genes Brain Behav. 2020; 19(6):e12678.

[48] Wang Y, Li J, Gao Y, et al. Hippo kinases regulate cell junctions to inhibit tumor metastasis in response to oxidative stress. Redox Biol. 2019; 26: 101233.

[49] Elhady M, Elazab AAAM, Bahagat KA, Abdallah NA, Ibrahim GES. Fatty pancreas in relation to insulin resistance and metabolic syndrome in children with obesity. J Pediatr Endocrinol Metab. 2019; 32(1): 19-26.

[50] Romana BS, Chela H, Dailey FE, Nassir F, Tahan V. Non-alcoholic fatty pancreas disease (NAFPD): a silent spectator or the fifth component of metabolic syndrome? A literature review. Endocr Metab Immune Disord Drug Targets. 2018; 18(6): 547-554.

[51] Lesmana CRA, Pakasi LS, Inggriani S, Aidawati ML, Lesmana LA. Prevalence of non-alcoholic fatty pancreas disease (NAFPD) and its risk factors among adult medical check-up patients in a private hospital: a large cross sectional study. BMC Gastroenterol. 2015; 15: 174.

[52] Katsiki N, Perez-Martinez P, Anagnostis P, Mikhailidis DP, Karagiannis A. Is nonalcoholic fatty liver disease indeed the hepatic manifestation of metabolic syndrome? Curr Vasc Pharmacol. 2018; 16(3): 219-227.

[53] Hung CS, Tseng PH, Tu CH, et al. Increased pancreatic echogenicity with US: relationship to glycemic progression and incident diabetes. Radiology. 2018; 287(3): 853-863.

[54] Nuñez-Durán E, Chanclón B, Sütt S, et al. Protein kinase STK25 aggravates the severity of non-alcoholic fatty pancreas disease in mice. J Endocrinol. 2017; 234(1): 15-27.

[55] Fraulob JC, Ogg-Diamantino R, Fernandes-Santos C, Aguila MB, Mandarim-de-Lacerda CA. A mouse model of metabolic syndrome: insulin resistance, fatty liver and non-alcoholic fatty pancreas disease (NAFPD) in C57BL/6 mice fed a high fat diet. J Clin Biochem Nutr. 2010; 46(3): 212-223.

[56] Yamazaki H, Tauchi S, Kimachi M, et al. Independent association between prediabetes and future pancreatic fat accumulation: a 5-year Japanese cohort study. J Gastroenterol. 2018; 53(7): 873-882.

[57] Wang CY, Ou HY, Chen MF, Chang TC, Chang CJ. Enigmatic ectopic fat: prevalence of nonalcoholic fatty pancreas disease and its associated factors in a Chinese population. J Am Heart Assoc. 2014; 3(1):e000297.

[58] Lammert E, Cleaver O, Melton D. Role of endothelial cells in early pancreas and liver development. Mech Dev. 2003; 120(1): 59-64.

[59] Choi CW, Kim Y, Kim JE, et al. Enhancement of lipid content and inflammatory cytokine secretion in SZ95 sebocytes by palmitic acid suggests a potential link between free fatty acids and acne aggravation. Exp Dermatol. 2019; 28(2): 207-210.

[60] Tersey SA, Levasseur EM, Syed F, et al. Episodic β-cell death and dedifferentiation during diet-induced obesity and dysglycemia in male mice. FASEB J. 2018; 32(11):fj201800150RR.

[61] Gezginci-Oktayoglu S, Sancar S, Karatug-Kacar A, Bolkent S. miR-375 induces adipogenesis through targeting Erk1 in pancreatic duct cells under the influence of sodium palmitate. J Cell Physiol. 2021; 236(5): 3881-3895.

[62] Fang T, Huang S, Chen Y, Chen Z, Chen J, Hu W. Glucagon like peptide-1 receptor agonists Alter pancreatic and hepatic histology and regulation of endoplasmic reticulum stress in high-fat diet mouse model. Exp Clin Endocrinol Diabetes. 2021; 129(9): 625-633.

[63] Dutour A, Abdesselam I, Ancel P, et al. Exenatide decreases liver fat content and epicardial adipose tissue in patients with obesity and type 2 diabetes: a prospective randomized clinical trial using magnetic resonance imaging and spectroscopy. Diabetes Obes Metab. 2016; 18(9): 882-891.

RIGHTS & PERMISSIONS

2024 The Author(s). Cell Proliferation published by Beijing Institute for Stem Cell and Regenerative Medicine and John Wiley & Sons Ltd.